Rammensee Hans-Georg, Weinschenk Toni, Gouttefangeas Cécile, Stevanović Stefan
Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
Immunol Rev. 2002 Oct;188:164-76. doi: 10.1034/j.1600-065x.2002.18815.x.
In this review, we discuss the possibilities for combining the power of molecular analysis of the antigens expressed in a given individual tumor with the design of a tailored vaccine containing defined antigens. Step 1 is a differential gene expression analysis of tumor and corresponding normal tissue. Step 2 is the analysis of human leukocyte antigen (HLA) ligands on tumor cells. Step 3 is data mining with the aim to select those antigens that might be suitable for tumor attack by the adaptive immune system. Step 4 is the on-the-spot clinical grade production of the constituents of the patient tailored vaccine, e.g. peptides. Step 5 is then vaccination and monitoring. Although it will not be possible to cover all relevant antigens expressed in a tumor, the antigens that can be identified with our present technical possibilities might be enough for improved immunotherapy. The scope of the present review is to explore the possibilities and the formidable technical and logistical challenge for such individual patient-oriented antigen definition to be used for therapeutic immunization.
在本综述中，我们讨论了将对特定个体肿瘤中表达的抗原进行分子分析的能力与设计包含特定抗原的定制疫苗相结合的可能性。第一步是对肿瘤组织和相应正常组织进行差异基因表达分析。第二步是分析肿瘤细胞上的人类白细胞抗原（HLA）配体。第三步是数据挖掘，目的是选择那些可能适合适应性免疫系统攻击肿瘤的抗原。第四步是现场临床级生产患者定制疫苗的成分，例如肽。然后第五步是接种疫苗和监测。虽然不可能涵盖肿瘤中表达的所有相关抗原，但凭借我们目前的技术可能性能够识别出的抗原可能足以改善免疫治疗。本综述的范围是探索将这种针对个体患者的抗原定义用于治疗性免疫的可能性以及巨大的技术和后勤挑战。
